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Background: Neurologic involvement in Behçet’s disease (BD), also known as neuro-Behcet’s 
disease (NBD), is one of the most devastating manifestations of the disease. The etiology of 
BD remains obscure and speculative. NBD usually occurs 1–10 years after the first symptom 
of BD has occurred, and its incidence is 18% (range of 4%–49%).
Objective: This study was conducted to describe the clinical and prognostic aspects 
of   neurologic involvement in BD among patients attending a multidisciplinary hospital 
clinic.
Methods: Eighty patients with BD were diagnosed according to the International Study Group 
Criteria for BD at our hospital. Sixteen patients (20%, including 11 men and five women) had 
evidence of and fulfilled the diagnostic criteria for NBD. These patients underwent laboratory 
and imaging investigations, including human leukocyte antigen-typing, lumbar puncture, elec-
troencephalographic studies, and computed tomography scanning.
Results: Fourteen of the 16 patients received high-dose steroids, and four of these 14 patients 
were treated with a combination of steroids and cytotoxic agents. Relief was observed in 14 
of 16 patients (87.5%). The remaining two patients were untreated males who suffered severe 
brainstem lesions, and later died.
Conclusion: In contrast with previous reports of a poor prognosis with NBD, our study shows 
that early aggressive intervention with corticosteroids and cytotoxic agents may ameliorate the 
prognosis in these patients, and can diminish and stabilize the negative effect of neurologic 
involvement.
Keywords: neuro-Behçet’s disease, neurologic involvement, aphthous ulceration, genital 
ulceration, iridocyclitis
Introduction
In 1937, Hulusi Behçet, a Turkish dermatologist, described a “triple symptom   complex” 
of aphthous ulceration, genital ulceration, and iridocyclitis1 (Figure 1). Since Behçet’s 
original description, many musculoskeletal, gastrointestinal,   urogenital, cardiac, 
  cutaneous, and neurologic symptoms have been attributed to Behçet’s disease (BD).2–4
Although the cause of BD is unknown, autoimmune, infectious, and genetic causes 
have been suspected. Environmental factors, such as microbial infections, are also 
suspected to be factors that contribute to the development of BD. Because BD has a 
characteristic geographic distribution spanning the Mediterranean basin and Asia, it 
is also known as “Silk Road” disease,5–6 the Silk Road being a geographic distribution 
along the historic route of commerce and travel between Europe and Asia. In fact, 
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from Eastern Asia to the Mediterranean.5 It is most common 
in Turkey (80–300/100,000),7 while the prevalence ranges 
from 10–20/100,000 in Japan, Korea, China, Iran, and Saudi 
Arabia.7–9 The prevalence of BD in Paris, France, in 2003 was 
reported to be 7.1/100,000, with rates of 2.4/100,000 in those 
of European ancestry, 34.6 in those of North African ancestry, 
and 17.5 in those of Asian ancestry.10–11 The prevalence ranges 
from 1/15,000 to 1/500,000 in Northern American (Olmsted 
County, MN) and Northern European countries.5
BD is somewhat more common in men in the Eastern 
Mediterranean area and in women in Northern European 
  countries, and typically affects young adults aged 20–40 years.5 
However, the epidemiology of the disease shows geographic 
variation, coupled with a similar variation in human leukocyte 
antigen (HLA)-B51 which has been reported to be associated 
strongly with the disease in high prevalence areas.12–15
Diagnosing BD can take a long time because   symptoms 
may wax and wane, and it may take months or even years 
to develop all of the symptoms. There is no cure, and 
treatment focuses on reducing pain and preventing serious 
  complications of the disease.
Currently, the most widely used diagnostic criteria 
for BD is the International Study Group’s classification16 
(Table 1), which requires recurrent oral ulceration plus two 
Oral ulcers
Genital ulcers  
Anterior uveitis and hypopyon  
Figure 1 Triple symptom complex commonly observed in Behcet’s disease: Aphthous ulceration, iridocyclitis, and genital ulceration. Aphthous ulceration often appears 
as the first symptom, ie, a painful, oval or round, shallow or deep, 1–20 mm lesion with central whitish or yellowish necrotic base and red halo. Almost always present 
during flares, and may precede other features by years. Iridocyclitis and ocular disease is usually more bilateral than unilateral, with anterior uveitis and hypopyon commonly 
observed. Retinal involvement may also be present, ie, retinal vasculitis/optic neuritis or atrophy and genital ulceration, which are similar in appearance and usually present 
as large ulcers which are deep and often cause scarring.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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of the   following in order to establish a definite diagnosis, ie, 
recurrent genital ulcerations, skin or eye lesions, or a positive 
pathology test.17 Although the diagnosis is made on the basis 
of the combination of typical clinical symptoms, radiologic 
findings of BD show characteristic features of gastrointesti-
nal, neurologic, cardiovascular, and thoracic organ system 
involvement.2
In the gastrointestinal tract, BD may produce various 
types of ulcers in the esophagus, stomach, and small and large 
intestines, as well as deeply penetrating ulcerations in the 
ileocecal region, frequently accompanied by enteric   fistulae. 
Neurologic involvement includes typical and a  typical 
parenchymal NBD, dural sinus thrombosis, cerebral arterial 
aneurysm, occlusion, dissection, and meningitis.2
Neurologic involvement in BD was first reported in 1941 
by Knapp,17 and the term “neuro-Behçet’s syndrome” was 
introduced by Cavara and D’Ermo in 1954.18
The reported rate of development of neurologic involve-
ment among BD patients ranges from 4% to 49%.19–23 It has 
been reported that neurologic involvement develops over a 
time interval of more than 10 years after the onset of BD,22,24 
and is classified as parenchymal or nonparenchymal.22,23
Parenchymal involvement primarily affects the   brainstem, 
spinal cord, and cerebral hemispheres. Nonparenchymal 
involvement includes intracranial hypertension, aseptic 
meningitis, cranial neuropathy, and cerebrovascular disorders 
such as dural sinus thrombosis, arterial dissection, occlusion, 
and aneurysm. Central nervous system (CNS) involvement 
is one of the most dangerous manifestations of BD.20
The disease tends to involve the white matter portion of the 
brain and brainstem, and may lead to headaches,   confusion, 
strokes, personality changes, and (rarely) dementia. BD may 
also involve the meninges, leading to meningitis. Because 
the meningitis of BD is not associated with any known infec-
tion, it is often referred to as “aseptic”   meningitis.25 NBD is 
commonly a motor–mental disorder, with a predilection for 
the brainstem and the basal ganglion region, as suggested 
by earlier neuropathology studies and neuroradiologic data. 
At the time of a neurologic attack, typical neuroradiologic 
findings have been defined.26
Polymorphonuclear pleocytosis and/or absence of IgG 
oligoclonal bands are suggestive of NBD. The presence of 
worse prognostic factors should be considered when treat-
ment is initiated. The presence of abnormal cerebrospinal 
fluid (CSF) and parenchymal involvement, especially of the 
“brainstem +” type, justifies more aggressive treatment.22
Vascular involvement is divided into three subsets, 
  including venous occlusion, arterial occlusion, and   arterial 
aneurysm.3 Cardiac manifestations include   intracardiac 
  thrombus, endomyocardial fibrosis, periaortic   pseudoaneurysm, 
and rupture of the sinus of Valsalva.2 Manifestations of BD in 
the thorax include pulmonary arterial   aneurysm, pulmonary 
arterial thromboembolism, and thrombosis in the superior vena 
cava, pulmonary infarction,   hemorrhage, and vasculitis of the 
pleura and pericardium.2,27
The various manifestations of BD respond to steroid 
  treatment.28 However, one of the characteristics of BD is a high 
rate of complications and recurrence after surgery.   Familiarity 
with its various radiologic and clinical characteristics is 
  essential for making an accurate early diagnosis and for prompt 
  treatment of patients with BD. Susceptibility to BD is strongly 
associated with the presence of the HLA-B51 allele,29–32 or 
HLA-B5, coupled by a negative lupus band test.
Although the pathogenesis of BD is largely unknown, 
associations with HLA-B51, genetic mutations including 
Factor V Leiden, and triggering by microbial antigens have 
been identified.33 Mutation of Factor V Leiden is recognized 
as the most common hereditary abnormality causing hyper-
coagulability, and is associated with BD.
NBD may present as acute focal or multifocal CNS 
dysfunction, and the clinical picture of NBD may resemble 
multiple sclerosis (MS).21,34–39
It has been observed that a substantial number of patients 
with NBD have a relapsing–remitting course while others 
Table 1 International Study Group criteria for Behçet’s disease16
Recurrent oral ulcerations Minor aphthous, major aphthous, or herpetiform ulceration observed by physician 
or patient, which recurred at least three times in one 12-month period.
Plus two of the following:  
  Recurrent genital ulceration Aphthous ulceration or scarring observed by physician or patient.
  eye lesion  Anterior uveitis, posterior uveitis, or cells in vitreous on slit lamp examination  
or retinal vasculitis observed by ophthalmologist.
  Skin lesion  erythema nodosum observed by physician or patient, pseudofolliculitis  
or papulopastular lesions, or acneform nodules observed by physician in  
postadolescent patients not on corticosteroid treatment.
  Positive pathergy test  Read by physician in 24–48 hours.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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may have a secondary progressive course. Some NBD 
patients have an insidious onset of the disease with primary 
progressive CNS dysfunction, and others may display symp-
toms attributable to intracranial hypertension associated with 
dural venous sinus thrombosis.40–42
Although nonneurologic involvement generally precedes 
neurologic findings, it may go unrecognized in some cases or 
may appear late in the course of BD, thus posing diagnostic 
difficulties.43–45 Peripheral nerve involvement, although 
reported in NBD, is relatively uncommon.46
The purpose of this investigation was to determine the 
frequency of the various neurologic symptoms in BD, to 
describe the clinical patterns of neurologic presentation in 
BD patients attending a multidisciplinary hospital clinic, 
and to examine the impact of neurologic disorders on the 
prognosis of the disease.
Methods
Eighty patients were identified as having been diagnosed with 
BD at our hospital during the previous 30 years. The   diagnosis 
was based on at least three of four criteria, ie,   aphthous 
  stomatitis, genital ulceration, ophthalmic lesions, and 
skin   erythema. Every patient suspected of   suffering from 
  neurologic symptoms was examined by a neurologist. The 
time interval elapsing between onset of the disease and 
  appearance of neurologic symptoms was recorded.
The 80 patients were diagnosed according to the 
  International Study Group’s classification (Table 1), which 
requires recurrent oral ulcerations plus two of the following 
in order to establish a definite diagnosis, ie, recurrent genital 
ulcerations, skin or eye lesions, and supported by neutrophil 
chemotaxis, HLA-B51, or HLA-B5, and coupled with a 
negative lupus band test. Sixteen patients (20%, including 11 
men and five women) had evidence of NBD. Fifteen of these 
patients were of Middle Eastern or North African origin, and 
one patient was an Ashkenazi Jew. Age of onset in our series 
was 18–38 (mean age 25.5) years. Age of onset of neurologic 
symptoms was 25–41 (mean 31.6) years. The time interval 
between onset of BD and neurologic manifestations varied 
widely, up to a maximum of 23 years. The 16 patients who had 
evidence of NBD underwent laboratory and imaging investiga-
tions. HLA-typing and electroencephalographic (EEG) studies 
were performed on all 16 patients, computed tomographic (CT) 
scan in 12, and lumbar puncture in 11 (Table 2).
Results
HLA-B51, which serves as an immunogenetic marker for 
a subgroup of patients with BD, was present in nine NBD 
patients, and HLA-B5 was present in two patients. EEG 
results were normal in nine patients, with three showing 
  diffuse slowing, two showing diffuse slowing and sharp 
waves, and other two having clinical convulsions. CT scan 
was normal in nine patients, with one patient showing a 
low-density lesion in the parietal lobe and in the brainstem, 
one patient having a low-density lesion in the brainstem, 
and another patient show sagittal sinus thrombosis. The 
remaining four patients refused to undergo a CT scan. With 
regard to CSF results, 11 patients had predominantly lym-
phocytic pleocytosis and two patients had positive oligoclo-
nal immunoglobulin G bands (Table 2). The most frequent 
neurologic manifestations were mild cognitive impairment 
(19%), severe headache (12.5%), convulsive disorders 
(12.5%), dural sinus thrombosis (6%), optic atrophy (19%) 
and other cranial nerve palsies (19%), hemispheric syn-
drome (19%), severe brainstem lesions (12.5%), pyramidal 
signs (19%), cerebellar signs (19%), myelopathy (20%), 
and peripheral neuropathy (6%, Table 3). Subacute onset 
and a relapsing-remitting course were the most commonly 
observed temporal patterns.
Treatment
Of 14 patients who received high-dose steroids, 13 were 
given prednisone 60–80 mg/day orally and one patient was 
treated with intravenous methylprednisolone 1000 mg/day, 
with gradual tapering of the dose. Four patients were treated 
with a combination of steroids and cytotoxic agents, namely 
Table 2 Results of laboratory investigations, eeG, CT scan, and 
CSF examination in 16 patients with BD
HLA-typing
  HLA-B51 9/16
  HLA-B5 2/16
  Others 5/16
EEG
  Normal 9/16
  Diffuse slowing 3/16
  Diffuse slowing and sharp waves multispike and sharp wave 2/16
  Discharges (clinical convulsions) 2/16
CT scan
  Normal 9/16
  Low density lesion in parietal lobe and in brainstem 1/16
  Low density lesion in brainstem 1/16
  Sagittal sinus thrombosis 1/16
  Not performed 4/16
CSF
  Mainly lymphocytic pleocytosis 11/16
  Oligoclonal IgG-positive 2/16
Abbreviations:  CSF,  cerebrospinal  fluid;  CT,  computed  tomography;  EEG, 
electroencephalogram; HLA, human leukocyte antigen; IgG, immunoglobulin G.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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azathioprine or chlorambucil. By the end of the treatment 
period, marked relief was observed in 87.5% of patients, 
except for two males who suffered severe brainstem lesions, 
did not receive any treatment, and subsequently died. One of 
these patients died three years after onset of severe neurologic 
symptoms, and the other died shortly after a brainstem stroke, 
having suffered from headache and a convulsive disorder 
for 30 years.
Discussion
Since the first description of BD in 1937,17 and the 
  subsequent first report of neurologic involvement in BD in 
1941,47 a plethora of studies of NBD have been reported. 
In   addition to the triad of symptoms commonly observed 
in BD, ie, aphthous ulceration, iridocyclitis, and genital 
ulceration, other multisystem disorders of unknown   etiology 
have been reported, and almost all organ systems can be 
involved.2–4 Clinical involvement of the CNS is in the range 
4%–49%.4,19–23,48
NBD can be mistaken for other CNS diseases with 
  multifocal presentations, such as multiple sclerosis (MS) and 
systemic lupus erythematosus (SLE), especially in the absence 
of systemic manifestations of BD.22 In the acute phase of 
NBD, large confluent lesions in the   brainstem-thalamic-basal 
ganglia region are highly suggestive of the disease, and can 
help to differentiate it from MS and SLE.26 In SLE, the lesions 
predominantly involve the subcortical white matter of the 
cerebral hemispheres and less frequently involve the basal 
ganglia or brainstem.26 In MS, the lesions are predominantly 
periventricular, with infrequent involvement of the basal 
ganglia and internal capsule.49 Moreover, brain stem lesions 
in MS are usually small, even in the acute stage, and seen 
along the floor of the fourth ventricle or anteriorly in the pons. 
This distribution contrasts with involvement of the central 
part of the pons in NBD.50 Spinal cord involvement in NBD 
tends to be extensive, whereas it rarely extends over more 
than two vertebral segments in MS.4
Neurologic involvement in BD is classified into 
  parenchymal and nonparenchymal.22,23 Parenchymal NBD 
is more common, and presents with attacks of hemiparesis, 
cognitive changes, and sphincter disturbance.20 This form of 
involvement has a predilection for the brainstem, thalamic, 
and basal ganglia regions. The junction of the midbrain and 
thalamus (mesodiencephalic junction) is characteristically 
involved and it is the most common neural parenchymal 
structure involved. The pontobulbar region is the next most 
commonly affected area.51–54
The disease involves the basal ganglia and internal 
  capsule region in one-third of the cases. The globus pallidus 
and posterior limb of the internal capsule are   characteristically 
involved, and lesions in the basal ganglia may extend along 
the corticospinal tracts to the cervical cord. It should be noted 
that several factors influence the course and prognosis of 
NBD; parenchymal involvement, especially of the brainstem, 
and high CSF cellular and/or protein content, are significantly 
associated with a worse prognosis.51–54
Sixteen patients (11 males and 5 females) in this series 
had evidence of NBD (Tables 2 and 3). Two deaths occurred in 
patients who had suffered from severe brainstem lesions for a 
long time and had received no treatment during their illness. In 
the other 14 patients, brainstem lesions were absent, and other 
neurologic manifestations, including cognitive impairment, 
sphincter disturbance, and pyramidocerebellar involvement 
were relatively mild. In fact, mild cognitive impairment was 
observed in 3/16 patients (  Mini-Mental state score 27, 28, 
and 29, possible total score 30).
Fourteen of the patients in this study improved or 
  stabilized after aggressive steroid treatment, and a number 
had two or more episodes of neurologic involvement, with 
improvement on steroid therapy (87.5%). In our view, their 
favorable prognosis was influenced by their stable clinical 
course and reduced disability. Certainly, early diagnosis 
and immediate administration of high-dose corticosteroid 
and cytotoxic therapy increased survival and decreased the 
disability and mortality in this patient series.
Conclusion
As described here, the clinical course of NBD may manifest 
in several ways, including a remittent form with a   progressive 
trend, called the “remittent type”, a remittent form that later 
becomes progressive, called the “remittent-progressive type”, 
and the “progressive or monophasic type”.
Table 3 Neurological manifestations observed among our patients
Dural sinus thrombosis 1/16 (6.25%)
Severe headache  2/16 (12.5%)
Cognitive derangement 3/16 (18.75%)
Optic atrophy 3/16 (18.75%)
Other cranial nerve palsies 3/16 (18.75%)
Hemispheric syndrome 3/16 (18.75%)
Brainstem lesions 2/16 (12.5%)
Pyramidal signs 3/16 (18.75%)
Cerebellar signs 3/16 (18.75%)
Myelopathy 3/16 (18.75%)
Cauda equina syndrome 1/16 (6.25%)
Peripheral neuropathy 1/16 (6.25%)
Convulsions 2/16 (12.5%)Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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The clinical course in our patients, except for the two 
deaths, was more benign, with two distinct patterns   identified, 
ie, a monophasic or biphasic form with almost complete 
  neurologic remission and a remittent or   polyphasic form with 
no significant neurologic deficit between relapses.
Early administration of steroids, or combined steroid 
and cytotoxic therapy, may have beneficially influenced our 
  findings. In contrast with previous reports of a poor prognosis 
in NBD, our study shows that immediate and aggressive 
treatment with corticosteroids and cytotoxic agents may 
ameliorate the prognosis in patients with mild to moderate 
NBD, and can diminish and stabilize the negative effect of 
neurologic involvement in the disease.
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